News & Articles

FEATURED ARTICLE

MRGPRX2: A Promising Target for Antibody Discovery in Allergy and Pain Disorders

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor X2), leading to mast cell degranulation and...

Read more

Browse articles by topic:

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

July 31, 2024

3 min read

After successful IND approval this past July, we are excited to announce the NK therapy NK510 received clinical trial approval from...

Read more →
IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

July 24, 2024

4 min read

In a groundbreaking development for the biotech industry, KACTUS's GMP-grade Cas9 has critically helped Yizun Bio secure IND clearance for a universal...

Read more →
FDA New Guidelines Pave the Way for Gene Editing Drug Development

FDA New Guidelines Pave the Way for Gene Editing Drug Development

April 24, 2024

2 min read

FDA Official Guidelines On January 31, 2024, the FDA CBER officially released the "Human Gene Therapy Products Incorporating Human Genome...

Read more →
Base Editing Technology Leads a New Chapter in Drug Development

Base Editing Technology Leads a New Chapter in Drug Development

February 14, 2024

5 min read

Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug development with its...

Read more →
RNP, an emerging powerful tool for gene delivery

RNP, an emerging powerful tool for gene delivery

February 2, 2024

5 min read

Through decades of rapid development, gene editing technology has officially entered the CRISPR 2.0 era, with new technologies such as...

Read more →
Empowering Gene Editing Therapy: The Atlas of Gene Editing Enzymes from KACTUS

Empowering Gene Editing Therapy: The Atlas of Gene Editing Enzymes from KACTUS

December 5, 2023

6 min read

Overview By leveraging its sophisticated ‘Structure Aided Design and Multiplex Screening (SAMS™)’ platform, along with extensive experience in process development...

Read more →
AccuBase™ Base Editor Enzyme: Globally In Stock Now

AccuBase™ Base Editor Enzyme: Globally In Stock Now

December 1, 2023

5 min read

Overview AccuBase™ is a new generation base editing tool independently developed by Base Therapeutics with exclusive global IP rights. AccuBase™ enzyme is...

Read more →
Global Release of the First Commercial Base Editor on the Market: AccuBase™

Global Release of the First Commercial Base Editor on the Market: AccuBase™

November 2, 2023

4 min read

KACTUS and Base Therapeutics announced their new strategic partnership to facilitate global manufacturing and sales of the GMP-grade base editor...

Read more →